1. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation
by Katayoun Rezvani, Matthias Grube, Jason M. Brenchley, Giuseppe Sconocchia, Hiroshi Fujiwara, David A. Price, Emma Gostick, Ko Yamada, Jan Melenhorst, Richard Childs, Nancy Hensel, Daniel C. Douek, and A. John Barrett
Blood
Volume 102(8):
October 15, 2003
©2003 by American Society of Hematology

2. CD8+ T-cell response to stimulation with the HLAA
CD8+ T-cell response to stimulation with the HLAA*0201–restricted peptides CMV pp65, PR1, WT1, and BCR-ABL in 18 healthy donors and 14 patients with CML. (A) CMV pp65.
CD8+ T-cell response to stimulation with the HLAA*0201–restricted peptides CMV pp65, PR1, WT1, and BCR-ABL in 18 healthy donors and 14 patients with CML. (A) CMV pp65. (B) PR1. (C) WT1. (D) BCR-ABL. CD8+-selected T cells were incubated for 3 hours either with unpulsed APC or with APC pulsed with 3 doses of peptide (0.1, 1, and 10 μM). Values represent copies of IFN-γ mRNA per 104 copies of CD8 mRNA. Because of limitation in the amount of PBMCs available, the intermediate dose testing was omitted in certain cases, and the data on intermediate and low avidity are presented together. The CD8+ T-cell response to stimulation with each particular peptide was calculated by subtraction of IFN-γ mRNA copies/104 CD8 copies induced by unpulsed APC (background) from that induced by peptide-pulsed APC. Values more than 100 IFN-γ mRNA copies per 104 copies of CD8 and at least 2 times that of background were defined as positive responses. Bars represent the median number of IFN-γ mRNA copies/104 CD8 copies for each condition. Responses to stimulation with PR1 and WT1 were signifi-cantly higher in the CML group. Responses to stimulation with BCR-ABL were detectable only in the CML group.
Katayoun Rezvani et al. Blood 2003;102:
©2003 by American Society of Hematology

3. CD8+ T cells (106) were stimulated with pp65 CMV peptide-pulsed T2 cells for 3 hours and then diluted logwise into unstimulated, autologous CD8+ T cells.
CD8+ T cells (106) were stimulated with pp65 CMV peptide-pulsed T2 cells for 3 hours and then diluted logwise into unstimulated, autologous CD8+ T cells. The number of CMV-specific CD8+ T cells in the starting material determined by tetramer assay was used to calibrate CMV-specific CD8+ T cells in each dilution and correlate this with the number of IFN-γ mRNA copies such that the lowest concentration contained one CMV-positive CD8+ T cell/106 nonstimulated CD8+ T cells. RNA was then extracted for qRT-PCR. The lower limit of detection by the tetramer and PCR assay was 1/ and 1/ CMV-specific CD8+ T cells, respectively.
Katayoun Rezvani et al. Blood 2003;102:
©2003 by American Society of Hematology

4. High- and low-avidity CD8+ T-cell responses determined by sensitivity to peptide concentration in healthy donors and patients with CML. Stimulating CD8+ T cells with 0.1 μM and 10 μM CMV pp65 (□), PR1 (○), WT1 (▵), and BCR-ABL (⋄) determined high- and low-a...
High- and low-avidity CD8+ T-cell responses determined by sensitivity to peptide concentration in healthy donors and patients with CML. Stimulating CD8+ T cells with 0.1 μM and 10 μM CMV pp65 (□), PR1 (○), WT1 (▵), and BCR-ABL (⋄) determined high- and low-avidity responses, respectively. Results shown are the ratios of high- to low-avidity CD8+ T-cell responses, calculated for individual healthy donors (filled symbols) and patients with CML (open symbols). Ratios were obtained by the following calculation: (number of IFN-γ mRNA copies/104 CD8 copies with 0.1 μM peptide)/(number of IFN-γ mRNA copies/104 CD8 copies with 10 μM peptide). Bars represent the median high- and low-avidity ratio for each condition. CD8+ T-cell responses to PR1, WT1, and BCR-ABL in patients with CML were mostly low avidity, whereas CD8+ T-cell responses in healthy donors were skewed toward high-avidity responses (P = .01 and P < .05, respectively). CMV responses were not statistically different in the 2 groups (P = .12). Dashed line represents a median ratio of 1.
Katayoun Rezvani et al. Blood 2003;102:
©2003 by American Society of Hematology

5. Phenotypic characterization of tetramer-positive CD3+CD8+ T cells.
Phenotypic characterization of tetramer-positive CD3+CD8+ T cells. Analysis of PBMCs was performed by 6-color flow cytometry in patients with CML patients before and after SCT and 2 healthy donors whose CD8+ T-cell frequencies to PR1 and WT1 were high enough to be visualized by tetramer staining. CD45RO, CD27, and CD57 phenotype of CD3/CD8-gated tetramer-positive lymphocytes was analyzed. Cells were gated on CD3+ lymphocytes, and the number in the top subpanel represents the percentage of CD3+ T cells that express CD8. Most of the CMV tetramer CD8+ T cells were CD45RO–CD27–CD57+ (blue), consistent with an effector memory phenotype (A). PR1 and WT1 tetramer-positive CD3+CD8+ T cells in 2 patients with CML before SCT and 2 patients after allogeneic SCT showed a mixture of CD45RO+CD27+CD57– (red) and CD45RO–CD27–CD57+ (blue), with most of the tetramer-gated cells showing the former phenotype (B-C). The same held true when PR1 and WT1 tetramer-positive T cells in 2 healthy donors were studied. Representative data are presented here. (A) CMV-positive control (UPN 283). (B) Patient with CML before SCT PR1 (UPN 210). (C) Patient with CML after SCT PR1 (UPN 319). (D) Patient with CML after SCT WT1 (UPN 319). (E) Healthy donor (UPN 12) WT1. (F) Healthy donor (UPN 2) PR1.
Katayoun Rezvani et al. Blood 2003;102:
©2003 by American Society of Hematology